2 unchanged sentences
10b5-1(c) or may represent a non-Rule 10b5-1 trading arrangement under the Exchange Act.
−Removed: During the quarter ended June 30, 2024, no such plans or other arrangements were adopted or terminated .
+Added: During the quarter ended September 30, 2024, no such plans or other arrangements were adopted or terminated .
See the Exhibit Index immediately following the signature page of this Quarterly Report on Form 10-Q.
1 unchanged sentence
ADMA Biologics, Inc.
−Removed: August 8, 2024
+Added: November 7, 2024
President and Chief Executive Officer
−Removed: August 8, 2024
+Added: November 7, 2024
/s/ Brad Tade
2 unchanged sentences
Exhibit Number
−Removed: Second Amended and Restated Bylaws of ADMA Biologics, Inc.
−Removed: (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed on June 28, 2024).
−Removed: Employment Agreement, dated April 1, 2024, by and between ADMA Biologics, Inc.
−Removed: and Kaitlin Kestenberg (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on April 2, 2024).
+Added: Employment Agreement, dated July 24, 2024, by and between ADMA Biologics, Inc.
+Added: and Brad Tade (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed on July 26, 2024).
Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
3 unchanged sentences
Certification of Principal Financial Officer pursuant to 18 U.S.C Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
−Removed: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended June 30, 2024, formatted in Extensible Business Reporting Language (XBRL):
−Removed: (i) Condensed Consolidated Balance Sheets as of June
−Removed: 30, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and six months ended June 30, 2024 and 2023, (iii) Condensed Consolidated Statements of Changes in Stockholders'
−Removed: Equity (Unaudited) for the three and six months ended June 30, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the six months ended June 30, 2024 and 2023, and (v) Notes to (Unaudited) Condensed
−Removed: Consolidated Financial Statements.
+Added: The following materials from ADMA Biologics, Inc.’s Form 10-Q for the quarter ended September 30, 2024, formatted in Extensible Business Reporting Language (XBRL):
+Added: (i) Condensed Consolidated Balance Sheets
+Added: as of September 30, 2024 (Unaudited) and December 31, 2023, (ii) Condensed Consolidated Statements of Operations (Unaudited) for the three and nine months ended September 30, 2024 and 2023, (iii) Condensed Consolidated Statements of
+Added: Changes in Stockholders' Equity (Unaudited) for the three and nine months ended September 30, 2024 and 2023, (iv) Condensed Consolidated Statements of Cash Flows (Unaudited) for the nine months ended September 30, 2024 and 2023, and (v)
+Added: Notes to (Unaudited) Condensed Consolidated Financial Statements.
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.